Kazia Therapeutics Propriété du management
Quel est le Propriété du management de Kazia Therapeutics?
Le Propriété du management de Kazia Therapeutics Limited est 20.95%
Quelle est la définition de Propriété du management?
La propriété d'un initié est calculée en divisant le nombre total d'actions possédées par des initiés (actionnaires détenant plus de 5% de la société ou un dirigeant ou un administrateur de la société) par le nombre total d'actions en circulation.
A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.
A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.
Propriété du management des entreprises dans Health Care secteur sur ASX par rapport à Kazia Therapeutics
Que fait Kazia Therapeutics?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Entreprises avec propriété du management similaire à Kazia Therapeutics
- ZOO Digital Plc a Propriété du management de 20.91%
- Clean Fuels Corp a Propriété du management de 20.92%
- Maisons du Monde S.A a Propriété du management de 20.92%
- ThyssenKrupp AG a Propriété du management de 20.93%
- Bel Fuse a Propriété du management de 20.93%
- Prism Resources a Propriété du management de 20.94%
- Kazia Therapeutics a Propriété du management de 20.95%
- Australian Vintage Ltd a Propriété du management de 20.96%
- McPhy S.A a Propriété du management de 20.96%
- Elanor Retail Property Fund a Propriété du management de 20.96%
- Tymbal Resources a Propriété du management de 20.96%
- Bentley Systems Inc a Propriété du management de 20.97%
- Bigblu Broadband plc a Propriété du management de 20.97%